Ataibeckley Inc Revenue Growth Rates (ATAI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ataibeckley Inc   (NASDAQ: ATAI)
 

ATAI's Revenue Growth by Quarter and Year

Ataibeckley Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATAI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.70
1st Quarter March 0.95
FY 2.65

ATAIs Annual Revenue
Ataibeckley Inc 's Revenue in the fiscal year 2025 $ 4.09 millions
Ataibeckley Inc 's Revenue in the fiscal year 2024 $ 0.31 millions
Ataibeckley Inc 's Revenue in the fiscal year 2023 $ 0.31 millions
Ataibeckley Inc 's Revenue in the fiscal year 2022 $ 0.23 millions
Ataibeckley Inc 's Revenue in the fiscal year 2021 $ 20.38 millions




ATAI Revenue second quarter 2026 Y/Y Growth Comment
Ataibeckley Inc reported Revenue surge of 136.67% year on year in the second quarter 2026, to $ 1.70 millions, this is lower than Ataibeckley Inc 's recent average Revenue surge of 144.21%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Revenue growth. While Ataibeckley Inc ' s Revenue doubling of 136.67% ranks overall at the positon no. 197 in the second quarter 2026.


ATAI Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -50 %
3rd Quarter September - 1775 % -55.56 % 350 %
2nd Quarter June 136.67 % 166.67 % 58.82 % 0 %
1st Quarter March -39.1 % - - -
FY   - 1266.67 % -6.25 % -

Financial Statements
Ataibeckley Inc 's second quarter 2026 Revenue $ 1.70 millions ATAI's Income Statement
Ataibeckley Inc 's second quarter 2025 Revenue $ 0.72 millions Quarterly ATAI's Income Statement


ATAI Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 42.67 % - -77.78 %
3rd Quarter September - 4.17 % -85.19 % -47.06 %
2nd Quarter June 79.37 % -53.85 % - 325 %
1st Quarter March -11.21 % - - 0 %
FY (Year on Year)   - 1266.67 % -6.25 % -


Back to ATAI Growth rate Comparisons >> Back to ATAI Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #59
Overall #197

Revenue Y/Y Growth Statistics
High Average Low
1772.5 % 144.21 % -100 %
(Jun 30 2026)   (Mar 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #59
Overall #197
Revenue Y/Y Growth Statistics
High Average Low
1772.5 % 144.21 % -100 %
(Jun 30 2026)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ataibeckley Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
364.86 % -8.15 % -100 %
(Jun 30 2023)  


ATAI's II. Quarter Q/Q Revenue Comment
Ataibeckley Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 79.37%, to $ 1.70 millions, from $0.95 millions in the first quarter.
ATAI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Ataibeckley Inc 's Revenue growth quarter on quarter, overall rank is 157.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #48
Overall #157
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #48
Overall #157
Revenue Q/Q Growth Statistics
High Average Low
364.86 % -8.15 % -100 %
(Jun 30 2023)  


ATAI's II. Quarter Q/Q Revenue Comment
Ataibeckley Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 79.37%, to $ 1.70 millions, from $0.95 millions in the first quarter.
ATAI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Ataibeckley Inc 's Revenue growth quarter on quarter, overall rank is 157.


Ataibeckley Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4.47 $ 3.49 $ 4.09 $ 3.02 $ 2.31
Y / Y Revenue Growth (TTM) 93.72 % 87.22 % - - -
Year on Year Revenue Growth Overall Ranking # 187 # 137 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 28.24 % -14.7 % 35.49 % 30.71 % 23.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 706 # 561 # 342 # 390 # 398


Cumulative Revenue growth Comment
With 93.72% annual Revenue growth, Ataibeckley Inc would report a record annual Revenue growth if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 137 to 187.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 51
Overall # 187

Revenue TTM Y/Y Growth Statistics
High Average Low
93.72 %
 90.47 %
87.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 146
S&P 500 # 706
Cumulative Revenue growth Comment
With 93.72% annual Revenue growth, Ataibeckley Inc would report a record annual Revenue growth if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 137 to 187.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 51
Overall # 187

Revenue TTM Y/Y Growth Statistics
High Average Low
93.72 %
90.47 %
87.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 146
S&P 500 # 706




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ATAI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions


About Ataibeckley Inc Revenue Growth Rates (ATAI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Atai Beckley N v (CIK 1840904).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-25-277583
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Atai Beckley N v ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.